1.63
-0.14(-7.91%)
Currency In USD
| Previous Close | 1.77 |
| Open | 1.75 |
| Day High | 1.77 |
| Day Low | 1.56 |
| 52-Week High | 3.71 |
| 52-Week Low | 0.53 |
| Volume | 5.15M |
| Average Volume | 7.89M |
| Market Cap | 14.87M |
| PE | -0.45 |
| EPS | -3.64 |
| Moving Average 50 Days | 1.04 |
| Moving Average 200 Days | 0.95 |
| Change | -0.14 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of October 23, 2025 at a share price of $1.63. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.55 as of October 23, 2025 at a share price of $1.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
GlobeNewswire Inc.
Oct 20, 2025 12:45 PM GMT
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI-2108 across fibrostenotic Croh
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
GlobeNewswire Inc.
Oct 13, 2025 12:45 PM GMT
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE NEWSWIRE)
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
GlobeNewswire Inc.
Oct 09, 2025 9:00 PM GMT
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammat